On May 1, 2025, renowned financial services firm Morgan Stanley released an updated analyst report regarding NeoGenomics (NEO, Financial), maintaining its current rating for the company while adjusting its price target.
Analyst Tejas Savant from Morgan Stanley maintained an "Equal-Weight" rating on NeoGenomics (NEO, Financial). While the rating remained unchanged from the previous assessment, the price target saw a significant revision.
The new price target set for NeoGenomics (NEO, Financial) is now $10.00 USD, down from the previous target of $17.00 USD. This change represents a decrease of 41.18% from the prior price target.
This adjustment by Morgan Stanley may influence investor sentiment regarding NeoGenomics (NEO, Financial) in upcoming trading sessions, given its notable shift in expected valuation.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 12 analysts, the average target price for NeoGenomics Inc (NEO, Financial) is $13.13 with a high estimate of $26.00 and a low estimate of $8.00. The average target implies an upside of 85.38% from the current price of $7.08. More detailed estimate data can be found on the NeoGenomics Inc (NEO) Forecast page.
Based on the consensus recommendation from 15 brokerage firms, NeoGenomics Inc's (NEO, Financial) average brokerage recommendation is currently 2.1, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for NeoGenomics Inc (NEO, Financial) in one year is $18.53, suggesting a upside of 161.72% from the current price of $7.08. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the NeoGenomics Inc (NEO) Summary page.
